Auxilium sues Watson on testosterone gel patent

Thu May 24, 2012 6:11pm IST

Related Topics

Stocks

   

(Reuters) - Auxilium Pharmaceuticals Inc sued Watson Pharmaceuticals Inc alleging that it infringed patents related to Auxilium's testosterone gel Testim.

A unit of Watson had filed with U.S. health regulators last month for the approval of a generic version of Testim.

As a result of the lawsuit, regulatory approval of Watson's generic version will be stayed for 30 months, or until the litigation is resolved, Auxilium said.

In its suit, Auxilium alleged that Watson's gel infringed ten patents that are expected to expire between 2023 and 2025.

Auxilium had entered into a co-promotion agreement with a unit of GlaxoSmithKline on Monday to jointly sell Testim.

Shares of Auxilium, which have risen 10 percent since the company entered into the GlaxoSmithKline agreement, closed at $19.23 on Wednesday on the Nasdaq. Watson shares were at $70.71 at close on the New York Stock Exchange on Wednesday.

(Reporting by Adithya Venkatesan in Bangalore; Editing by Sreejiraj Eluvangal)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Disease Outbreak

REUTERS SHOWCASE

Reading the Brain

Reading the Brain

Guilt may spoil restorative effects of entertainment.  Full Article 

Heart Matters

Heart Matters

Weekday heart attacks still getting quicker treatment at hospitals.  Full Article 

Tackling Stress

Tackling Stress

'Interreality' may enhance stress therapies.  Full Article 

Jogging Helps

Jogging Helps

Short jogs linked to lower risk of death from heart disease.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage